News Releases
Polydex Pharmaceuticals Limited is dedicated to providing timely information to shareholders and the public at large. You are invited to contact us with any questions you may have. You can visit our contact page and submit your inquiry, or e-mail us directly at PolydexIR@gmail.com. Become a subscriber today and we will be sure to send you news as it is published.
Polydex Pharmaceuticals Issues Third Quarter Financial Results
Company Showing Signs of Improvement for 4th Quarter
Toronto, Ontario, December 15, 2022 – Polydex Pharmaceuticals Limited (OTC Pink:POLXF) (the “Company”) reports financial results for its third quarter of fiscal 2023, the period ended October 31, 2022. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues Second Quarter Financial Results
Balance Sheet Remains Strong, Despite Slow Economic Recovery
Toronto, Ontario, September 15, 2022 – Polydex Pharmaceuticals Limited (OTC Pink:POLXF) (the “Company”) reports financial results for its second quarter of fiscal 2023, the period ended July 31, 2022. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues First Quarter Financial Results
Management Optimistic With Year Over Year Improvement
Toronto, Ontario, June 15, 2022 – Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) reports financial results for its first quarter of fiscal 2023, the period ended April 30, 2022. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues Year End Financial Results
Management Pursuing New Opportunities an Markets for Product Line
Toronto, Ontario, May 2, 2022 – Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) reports financial results for its fiscal year ended January 31, 2022. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues Third Quarter Financial Report
Management continues prudent cash management
to weather global challenges
Toronto, Ontario, December 15, 20201 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for the second quarter of fiscal 2021, the period ending July31, 2020. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues Second Quarter Financial Report
Financial Results Improved Over First Quarter despite
Unprecedented Global Challenges
Toronto, Ontario, September 15, 2021 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for the second quarter of fiscal 2022, the period ending July31, 2021. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues First Quarter Financial Report
Prudent Cash Management Sustains Company Through Adverse Conditions
Toronto, Ontario, June 15, 2021 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for the first quarter of fiscal 2022, the period ending April 30, 2021. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues Year End Financial Results
Company remains profitable in Global Pandemic
Toronto, Ontario, April 30, 2021 – Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) reports financial results for its fiscal year ended January 31, 2021. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues Third Quarter Financial Report
Company remains profitable with strong balance sheet and cash position
Toronto, Ontario, December 15, 2020 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for the third quarter of fiscal 2021, the period ending October 31, 2020. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues Second Quarter Financial Report
Increase in Sales Keeps Company Profitable
Toronto, Ontario, September 15, 2020 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for the second quarter of fiscal 2021, the period ending July31, 2020. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues First Quarter Financial Report
Company Remains Profitable During Global Business Reduction
Toronto, Ontario, June 15, 2020 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for the first quarter of fiscal 2021, the period ending April 30, 2020. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Provides Year End Financial Report
Closing The Year With a Strong Cash Position and Low Debt
Toronto, Ontario, April 30, 2020 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for its fiscal year ended January 31, 2020. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues Third Quarter Results
With Continued Improving Margins
Toronto, Ontario, December 16, 2019 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) announces 3rd quarter financial results, for the third quarter of fiscal 2020, including the three-month and nine-month periods ended October 31, 2019, are shown together with comparative figures from the same periods in the previous fiscal year, and reported in U.S. dollars.
Polydex Pharmaceuticals Issues Second Quarter Results
Positive Cash Flow Key to Forward Momentum
Toronto, Ontario, September 16, 2019 – Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) is pleased to report financial results for the second quarter of fiscal 2020, the period ending July 31, 2019. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues First Quarter Results
Net Profit up for the Quarter
Toronto, Ontario, June 17, 2019 – Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) is pleased to report financial results for the first quarter of fiscal 2020, the period ending April 30, 2019. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Ltd. Reports 3rd Quarter Financial Results
with consistent year over year sales.
The Company appoints new CFO David Jamestee
following the retirement of John Luce.
Toronto, Ontario, December 17, 2018 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) announces 3rd quarter financial results.
Polydex Pharmaceuticals Issues Second Quarter Results
Sales Remain Consistent, Profits Up
Toronto, Ontario, September 14, 2018 – Polydex Pharmaceuticals Limited
(OTC/Pink:POLXF) (the “Company”) today announced financial results for the second quarter of the 2019 fiscal year. The three-month and six-month periods ending July 31, 2018 (together with comparative figures from the same periods in the previous fiscal year) are reported in U.S. dollars.
Polydex Pharmaceuticals Issues First Quarter Results
Continued Profitability and Increased Unit Sales in U.S.
Toronto, Ontario, June 15, 2018 – Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) reports financial results for the first quarter of fiscal 2019, the period ending April 30, 2018. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Issues First Quarter Results
New Product Development Should Lead to Increased Sales
Toronto, Ontario, June 15, 2017 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for the first quarter of fiscal 2018, the period ending April 30,2017. All figures are reported in US dollars.
Polydex Pharmaceuticals Provides Year End Financial Report
Annual Sales Increased by 9.6%
Profitability sustained for 4 consecutive years
Toronto, Ontario, May 1, 2017 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for its fiscal year ended January 31, 2017.
Polydex Reports 3rd Quarter Financials
Continued Strong Sales & Increased Gross Profit
Toronto, Ontario, December 15th, 2016 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF)(the “Company”) is pleased to provide 3rd quarter financial results. Sales remain strong, and continued attention to cost control leads to increased gross profit...
Polydex President & CEO George Usher to participate at Water Innovation in Action Conference
Waste Water Sysytems Implemented at Dextran Products
To be Focus of Session: Cross-Pollinating to Solve Water Challenges
Toronto, Ontario, October 17th, 2016 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF)(the “Company”) today announced George Usher, President and CEO of the company will be...
Polydex Issues Second Quarter Financial Report
Sales continue to grow, up 3% from 2016 Q2
43% increase in Gross Profits over same period last year
Toronto, Ontario, Sept 15th, 2016 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF)(the “Company”) today announced financial results for the second quarter of fiscal 2017, the period ending July 31, 2016.(together with comparativefigures from the same periods in the previous fiscal year) All figures are reported in US dollars....
Polydex Issues First Quarter Financial Report
More Than Three Years of Sustained Profitabilty
Despite Impact of Currency Exchange
Toronto, Ontario, June 14th, 2016 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF)(the “Company”) reports financial results for the first quarter of fiscal 2017, the period ending April 30, 2016. All figures are reported in US dollars....
Polydex Secures New Bank Financing
Toronto, Ontario, March 1st, 2016 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF)(the “Company”) announces that due to the continuing improvement of operations, its wholly owned subsidiary, Dextran Products Limited, has secured traditional bank financing to replace the existing private mortgage at a lower rate, and has also secured...
Polydex Files OTC Market Disclosure Documents
Stop Sign Removed
Toronto, Ontario, February 29, 2016 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF)(the “Company”) announces the filing of all of the required statements in order to be considered as providing current information to the public. As a result...
Polydex Reports 3rd Quarter Financial Results
9% Increase in Sales and 300% Increase in Net Income
Eleven Consecutive Quarters with Sustained Profitability
Conservative Practices to Reduce Utilities Expenses
Toronto, Ontario, December 15, 2015 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) is pleased to provide 3rd quarter financial results,
Polydex Reports 2nd Quarter Financial Results
To 32% Increase in Sales leads to 150% Increase in Gross Profit
Toronto, Ontario, September 15, 2015 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) today announced financial results for the second quarter of fiscal 2016. The three-month and six-month periods ending July 31, 2015 (together with comparative figures from the same periods in the previous fiscal year) are reported in U.S. dollars.
Polydex Pharmaceuticals Appeals to Shareholders
To Participate in Online Voting for AGM
Toronto, Ontario, August 25, 2015 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) will be holding its Annual General Meeting at 10:00am, local time, on August 28, 2015, at the principal offices of the Company located at 421 Comstock Road, Toronto, Ontario, Canada, M1L 2H5.
Polydex Pharmaceuticals Reminds Shareholders of AGM
New Voting Procedures
Toronto, Ontario, August 17, 2015 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) will hold its Annual General Meeting at 10:00am, local time, on August 28, 2015, at the principal offices of the Company located at 421 Comstock Road, Toronto, Ontario, Canada, M1L 2H5.
Polydex Pharmaceuticals Extends Invitation to AGM
Advises on Voting Procedures
Toronto, Ontario, July 20, 2015 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) announced that its Annual General Meeting is to be held at 10:00am, local time, on August 28, 2015, at tyhe principal offices of the Company located at 421 Comstock Road, Toronto, Ontario, Canada, M1L 2H5.
Polydex Pharmaceuticals Issues First Quarter Financials
329% Increase in Profit over last year's First Quarter
Toronto, Ontario, June 10, 2015 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for its first quarter of fiscal 2016, the period ending April 30, 2015. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Provides Year End Financial Report Two Full Years of Sustained Profitability, Auditor Removes Going Concern
New Equipment Installed, Orders Continue to Rise
Outsourced Production Aims to Increase Sales & Profit
Toronto, Ontario, April 30, 2015 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for its fiscal year ended January 31, 2015. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Reports 3rd Quarter Results
Strong Fundamentals Result in Sustained Profitability
Toronto, Ontario, December 15, 2014 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) is pleased to annouce sustained profitability for the seventh straight quarter, as a result of Management's diligent focus on cost control, capital improvements, and attention to customer service.
Polydex Pharmaceuticals Reports 2nd Quarter Results
Equipment Upgrades and Continued Profitability
Toronto, Ontario, September 9, 2014 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports that it has continued to invest in planned capital improvements for essential equipment which should allow for more consistent production. Customer interest continues to grow as reflected in our strong order book.
Polydex Pharmaceuticals Issues First Quarter Financial Results
Profitabilty Remains a Priority while Facility Upgrades Planned
Toronto, Ontario, June 10, 2014 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for the first quarter of fiscal 2015, the period ending April 30, 2014. All figures are reported in US dollars.
Polydex Pharmaceuticals Provides Year End Financial Report Showing Sales Up 14.8% and Margins Increased to 24%
Product Demand Drives EBITDA to a Gain of $837,645 from a Loss of $200,463
Toronto, Ontario, May 1, 2014 – Polydex Pharmaceuticals Limited (OTC/Pink:POLXF) (the “Company”) reports financial results for its fiscal year ended January 31, 2014. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Reports 3rd Quarter Financial Results
Profitability Continues for Third Straight Quarter
Toronto, Ontario, December 11, 2013 - Polydex Pharmaceuticals Limited (Pink/OTCBB:POLXF) has published its third quarter financial report, and is pleased to announce another profitable quarter this fiscal year as a result of continued high demand from customers and increased
Polydex Pharmaceuticals Issues 2nd Quarter Financial Results
Continued Robust Sales & Earnings
Facility Improvements to Reduce Production Costs
Toronto, Ontario, September 16, 2013 - Polydex Pharmaceuticals Limited (OTC Pink:POLXF) (the "Company") reports that it has continued to experience high demand for product from its customers, resulting in increasing sales and collaborated investments
Polydex Pharmaceuticals Enters New US License Agreement
Receiving $250,000 at Signing and a
Second $250,000 on Approval of ANADA
Toronto, Ontario, July 30, 2013 - Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the "Company") is please to annouce that through it's wholly owned subsidary it has received $250,000 for issuing a new exclusive 10-year supply agreement
Polydex Pharmaceuticals Issues First Quarter Financial Results
Sales and Profit Margins Up Resulting in Return to Profitability
Toronto, Ontario, June 10, 2013 - Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the "Company") reports financial results for the first quarter of fiscal 2014, the three-month period ending April 30, 2013. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Reports Strong Backlog
Resulting from Worldwide Increase in Demand for Product in 2013
Fiscal Year End Financial Results
Toronto, Ontario, April 30,2013 - Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the "Company") reports financial results for its fiscal year ended January 31, 2013. All figures are reported in U.S. dollars.
Polydex Pharmaceuticals Reports 3rd Quarter Financial Results
High Demand for Product Temporarily Strains Production Equipment Getting Back on Track
Toronto, Ontario, December 14, 2012 - Polydex Pharmaceuticals Limited (Pink/OTCBB:POLXF) reports financial results for its third fiscal quarter, the three-month period ended October 31, 2012.